Drugmaker Pays $2.6 Million Over Off-Label Marketing
Drugmaker Cephalon has paid more than $2.6 million to the state of Nebraska to settle allegations of off-label marketing of three pharmaceutical products. The settlement resolves allegations that Cephalon marketed drugs for uses not approved by the Federal Drug Administration. The drugs are the painkiller Actiq, the anti-seizure drug Gabitril and the sleep-disorder drug Provigil. The money is part of a $425 million national settlement with state Medicaid programs.
on Dec 31st, 2008 at 6:41 pm
[...] unknown wrote an interesting post today onDrugmaker Pays $2.6 Million Over Off-Label Marketing | Legal Jobs …Here’s a quick excerptDrugmaker Cephalon has paid more than $2.6 million to the state of Nebraska to settle allegations of off-label marketing of three pharmaceutical products. The settlement resolves allegations that Cephalon marketed drugs for uses not … [...]